Department of Anaesthesia, York Teaching Hospital NHS Foundation Trust, York, UK.
Br J Anaesth. 2014 Feb;112(2):281-9. doi: 10.1093/bja/aet307. Epub 2013 Sep 20.
Goal-directed fluid therapy has been shown to improve outcomes after colorectal surgery, but the optimal type of i.v. fluid to use is yet to be established. Theoretical advantages of using hydroxyethyl starch (HES) for goal-directed therapy include a reduction in the total volume of fluid required, resulting in less tissue oedema. Recent work has demonstrated that new generations of HES have a good safety profile, but their routine use in the perioperative setting has not been demonstrated to confer outcome benefit.
We randomly assigned 202 medium to high-risk patients undergoing elective colorectal surgery to receive either balanced 6% HES (130/0.4, Volulyte) or balanced crystalloid (Hartmann's solution) as haemodynamic optimization fluid. The primary outcome measure was the incidence of gastrointestinal (GI) morbidity on postoperative day 5. Secondary outcome measures included the incidence of postoperative complications, hospital length of stay, and the effect of trial fluids on coagulation and inflammation.
No difference was seen in the number of patients who suffered GI morbidity on postoperative day 5 [30% in the HES group vs 32% in the crystalloid group; adjusted odds ratio=0.96 (0.52-1.77)]. Subjects in the crystalloid group received more fluid [median (inter-quartile ranges) 3175 (2000-3700) vs 1875 (1500-3000) ml, P<0.001] and had a higher 24 h fluid balance [+4226 (3251-5779) vs +3610 (2443-4519) ml, P<0.001]. No difference in the incidence of postoperative complications was seen between the groups.
Goal-directed fluid therapy is possible with either crystalloid or HES. There is no evidence of a benefit in using HES over crystalloid, despite its use resulting in a lower 24 h fluid balance.
目标导向的液体治疗已被证明可以改善结直肠手术后的结果,但使用哪种静脉输液仍有待确定。使用羟乙基淀粉(HES)进行目标导向治疗的理论优势包括减少所需的总液体量,从而减少组织水肿。最近的研究表明,新一代 HES 具有良好的安全性,但在围手术期常规使用并未证明能带来获益。
我们将 202 名接受择期结直肠手术的中高危患者随机分为接受平衡 6% HES(130/0.4,Volulyte)或平衡晶体液(哈特曼溶液)作为血流动力学优化液的组。主要观察终点是术后第 5 天胃肠道(GI)发病率。次要观察终点包括术后并发症的发生率、住院时间以及试验液对凝血和炎症的影响。
第 5 天 GI 发病率无差异[HES 组 30%,晶体液组 32%;调整后的优势比=0.96(0.52-1.77)]。晶体液组的患者接受了更多的液体[中位数(四分位间距)3175(2000-3700)比 1875(1500-3000)ml,P<0.001],且 24 小时液体平衡更高[+4226(3251-5779)比 +3610(2443-4519)ml,P<0.001]。两组术后并发症的发生率无差异。
用晶体液或 HES 都可以进行目标导向的液体治疗。尽管 HES 治疗导致 24 小时液体平衡较低,但与晶体液相比,HES 并没有获益的证据。